ClinicalTrials.gg
CompletedNCT05431387ORCA-V1Updated Jan 14, 2026Results posted

A Study of Cytisinicline for Vaping Cessation in Adult Smokers

A Phase 2 interventional study of cytisinicline and Placebo in Vaping and E-Cig Use, sponsored by Achieve Life Sciences. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by Achieve Life Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 287 studies in Vaping with a site in United States — 65 open to participants now, 73 under way, 1 of them phase 3. Vaping · United States.

Enrollment
79th of 257
160 · median 71
Started
2022
with 32 others
Phase 2
18 of 287
6 open now
Registered
161st of 287
by date

Among the 287 studies in Vaping with a site in United States, this one is the 79th largest by enrollment of the 257 interventional ones that give a count, is one of 33 that started in 2022, is one of 18 in phase 2, and was the 161st registered.

Vaping

403 studies on the registry are indexed under Vaping; 96 are open to participants now.

Browse Vaping studies →

Open to participants now

65 of the 287 studies in Vaping with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 64 Vaping studies recruiting now, 32 (50%) set no upper age limit and 31 (48%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 287 studies in Vaping with a site in United States, or all of them as a file.
02

Study summary

This placebo-controlled Phase 2 study is being conducted at sites within the United States to evaluate the efficacy and safety profile of 3 mg cytisinicline administered TID for 12 weeks for vaping cessation.

03

Conditions studied

  • Vaping
  • E-Cig Use

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects, age ≥ 18 years.
  2. Test positive for cotinine using the Alere iScreen® OFD Cotinine Oral Fluid Screening Device (Positive testing at ≥ 30 ng/mL cotinine level).
  3. Current daily nicotine-containing electronic cigarette usage as recorded in a screening diary for at least 7 consecutive days. Willing to bring the e-cigarette or nicotine device used to the clinical site so that the specific product type, flavor, and nicotine level can be documented.
  4. Willing to initiate study treatment on the day after randomization and set a quit date within 7-14 days of starting treatment.
  5. Willing to actively participate in the study's vaping cessation behavioral support provided throughout the study.
  6. Able to fully understand study requirements, willing to participate, and comply with dosing schedule.
  7. Sign the Form.

Exclusion criteria

Exclusion Criteria:

  1. Currently smoking, or having smoked within 4 weeks prior to study randomization, any combustible cigarettes, other combustible tobacco products or non-combustible tobacco products (such as heat not burn products) (i.e., dual users).
  2. Expired carbon monoxide (CO) levels ≥ 10 ppm, indicating recent combustible tobacco use.
  3. More than 1 study participant in same household during the study treatment period.
  4. Known to cytisinicline or any of the .
  5. Positive urinary drugs of abuse screen determined within 28 days before the first dose of cytisinicline (Note: tetrahydrocannabinol (THC) is not part of the abuse screen).
  6. abnormal serum chemistry or hematology values within 28 days of randomization (i.e., requiring treatment or monitoring).
  7. Clinically significant abnormalities in 12-lead determined after minimum of 5 minutes in supine position within 28 days of randomization (i.e., requiring treatment or further assessment).
  8. Recent history (within 3 months) of acute myocardial infarction, unstable angina, stroke, cerebrovascular incident or hospitalization for congestive heart failure.
  9. Current uncontrolled hypertension (blood pressure ≥ 160/100 mmHg).
  10. Documented diagnosis of schizophrenia or bipolar psychiatric illness; currently psychotic; having suicidal ideation within the last 3 months (corresponding to question 4 or 5 on the Columbia - Suicide Severity Rating Scale [C-SSRS]); or current symptoms of moderate to severe depression (depression score ≥ 11 on the HADS) within the last 3 months.
  11. Renal impairment defined as a (CrCl) \< 60 mL/min (estimated with the Cockroft-Gault equation).
  12. Hepatic impairment defined as (ALT) or aspartate aminotransferase (AST) > 2.0 x the (ULN).
  13. Recent history or symptoms (within 4 weeks of randomization) of unstable respiratory disease (e.g., pneumonia, product-use associated lung injury or e-cigarette or vaping use-associated lung injury [EVALI], etc.)
  14. Women who are pregnant or breast-feeding.
  15. Male or female subjects of who do not agree to use acceptable methods of starting at the time of consent, during the study treatment period, and continuing for one month after ending study treatment.
  16. Participation in a clinical study with an drug in the 4 weeks prior to study randomization.
  17. Use of other smoking cessation medications (bupropion, varenicline, nortriptyline, or any nicotine replacement therapy [NRT]) in the 4 weeks prior to study randomization, any previous cytisinicline use, or planned use of these or other nicotine replacement medications during the study.
  18. Any planned use during the study of combustible cigarettes or other nicotine-containing, non-vaping products (e.g., pipe tobacco, cigars, snuff, smokeless tobacco, hookah, ZYN pouches, etc).
  19. Any other reason that the investigator views the subject should not participate or would be unable to fulfill the requirements for the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (actual)

Study arms

  • Placebo comparator
    Placebo + Behavioral Support

    one placebo tablet orally (PO) three times daily (TID) plus behavioral support for 12 weeks

    Drug: Placebo · Behavioral: Behavioral support

  • Experimental
    Cytisinicline + Behavioral Support

    one cytisinicline tablet PO TID plus behavioral support for 12 weeks

    Drug: cytisinicline · Behavioral: Behavioral support

Interventions

  • film-coated oral tablets containing 3 mg cytisinicline

    Also known as: cytisine

  • DrugPlacebo

    film-coated oral tablets containing matched placebo

  • BehavioralBehavioral support

    Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the participant about their attempt to quit vaping. Each session will last approximately 10 minutes.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Vaping Abstinence From Week 9 to 12

    Vaping abstinence verified weekly using quantitative saliva cotinine levels at \< 10 ng/mL for biochemical verification and participants' self-report of no vaping.

    Time frame: Weeks 9 to 12

Secondary outcomes

  1. Percentage of Participants With Vaping Abstinence From Week 3 to 6

    Vaping abstinence verified weekly using quantitative saliva cotinine levels at \< 10 ng/mL for biochemical verification and participants' self-report of no vaping.

    Time frame: Weeks 3 to 6

  2. Percentage of Participants With Vaping Abstinence From Week 6 to 9

    Vaping abstinence verified weekly using quantitative saliva cotinine levels at \< 10 ng/mL for biochemical verification and participants' self-report of no vaping.

    Time frame: Weeks 6 to 9

  3. Percentage of Participants Who Achieve Vaping Abstinence at Each Visit From Week 2 and Week 12 (Seven-Day Point Prevalence Rates)

    The 7-day point prevalence abstinence endpoints are binary (success, failure), defined at each of the following visits: Week 2 to Week 12. Vaping abstinence used quantitative saliva cotinine levels at \< 10 ng/mL for biochemical verification and participants' self-report of no vaping in the past 7 days.

    Time frame: Weeks 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

  4. Changes From Baseline in Quantitative Cotinine Levels From Week 2 to Week 12

    Changes in nicotine vaping measured by weekly quantitative cotinine levels from Week 2 to Week 12.

    Time frame: Baseline, Weeks 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

  5. Percentage of Participants With Vaping Abstinence From Week 9 to 16

    Vaping abstinence used quantitative saliva cotinine levels at \< 10 ng/mL for biochemical verification and participants' self-report of no vaping. Measurements were Weekly from Week 9 to 12 and one month for Week 16.

    Time frame: Weeks 9 to 16

07

Results

Posted Jan 14, 2026

Participant flow

Participant flow — Overall Study
MilestonePlacebo + Behavioral SupportCytisinicline + Behavioral Support
Started53107
Randomized and treated53106
Completed4289
Not completed1118
Withdrew: Adverse event10
Withdrew: Withdrawal by subject44
Withdrew: Physician decision01
Withdrew: Lost to follow-up59
Withdrew: Other, not specified14

Outcome measures

PrimaryPercentage of Participants With Vaping Abstinence From Week 9 to 12

Vaping abstinence verified weekly using quantitative saliva cotinine levels at \< 10 ng/mL for biochemical verification and participants' self-report of no vaping.

Time frame:
Weeks 9 to 12
Reported as:
Number · percentage of participants
Percentage of Participants With Vaping Abstinence From Week 9 to 12
percentage of participantsPlacebo + Behavioral SupportCytisinicline + Behavioral Support
Percentage of Participants With Vaping Abstinence From Week 9 to 1215.131.8
Statistical analysis
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.0350 (Two-sided, calculated by exact computations with whether subjects had smoked \>100 cigarettes in their lifetime (yes, no) as stratification.) · Odds ratio (or): 2.64 · 95% CI 1.062 to 7.098Common odds ratio
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.0348 (Derived from marginal odds ratio.) · Odds ratio (or): 2.62 · 95% CI 1.133 to 6.491Marginal (unadjusted) odds ratio
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Cochran-Mantel-Haenszel · p = 0.0120 (p-value for difference in proportions) · Difference in proportions: 0.17 · 95% CI 0.012 to 0.284
SecondaryPercentage of Participants With Vaping Abstinence From Week 3 to 6

Vaping abstinence verified weekly using quantitative saliva cotinine levels at \< 10 ng/mL for biochemical verification and participants' self-report of no vaping.

Time frame:
Weeks 3 to 6
Reported as:
Number · percentage of participants
Percentage of Participants With Vaping Abstinence From Week 3 to 6
percentage of participantsPlacebo + Behavioral SupportCytisinicline + Behavioral Support
Percentage of Participants With Vaping Abstinence From Week 3 to 615.124.3
Statistical analysis
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.2205 · Odds ratio (or): 1.81 · 95% CI 0.766 to 4.551Marginal (unadjusted) odds ratio
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Difference in proportions: 0.09 · 95% CI -0.058 to 0.209
SecondaryPercentage of Participants With Vaping Abstinence From Week 6 to 9

Vaping abstinence verified weekly using quantitative saliva cotinine levels at \< 10 ng/mL for biochemical verification and participants' self-report of no vaping.

Time frame:
Weeks 6 to 9
Reported as:
Number · percentage of participants
Percentage of Participants With Vaping Abstinence From Week 6 to 9
percentage of participantsPlacebo + Behavioral SupportCytisinicline + Behavioral Support
Percentage of Participants With Vaping Abstinence From Week 6 to 917.030.8
Statistical analysis
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.0850 · Odds ratio (or): 2.18 · 95% CI 0.967 to 5.202Marginal (unadjusted) odds ratio
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Difference in proportions: 0.14 · 95% CI -0.019 to 0.263
SecondaryPercentage of Participants Who Achieve Vaping Abstinence at Each Visit From Week 2 and Week 12 (Seven-Day Point Prevalence Rates)

The 7-day point prevalence abstinence endpoints are binary (success, failure), defined at each of the following visits: Week 2 to Week 12. Vaping abstinence used quantitative saliva cotinine levels at \< 10 ng/mL for biochemical verification and participants' self-report of no vaping in the past 7 days.

Time frame:
Weeks 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Vaping Abstinence at Each Visit From Week 2 and Week 12 (Seven-Day Point Prevalence Rates)
percentage of participantsPlacebo + Behavioral SupportCytisinicline + Behavioral Support
Week 27.514.0
Week 322.633.6
Week 424.549.5
Week 528.342.1
Week 624.541.1
Week 722.648.6
Week 824.543.0
Week 924.542.1
Week 1028.341.1
Week 1124.537.4
Week 1222.638.3
Statistical analysis
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.3038 (Two-sided, derived from marginal (unadjusted) odds ratio.) · Odds ratio (or): 2.00 · 95% CI 0.653 to 7.309
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.3038 (Two-sided, derived from marginal odds ratio.) · Difference in proportions: 0.06 · 95% CI -0.058 to 0.144
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.1996 (Two-sided, derived from marginal (unadjusted) odds ratio.) · Odds ratio (or): 1.73 · 95% CI 0.817 to 3.800
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.1996 (Two-sided, derived from marginal odds ratio.) · Difference in proportions: 0.11 · 95% CI -0.055 to 0.251
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.0035 (Two-sided, derived from marginal (unadjusted) odds ratio.) · Odds ratio (or): 3.02 · 95% CI 1.458 to 6.414
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.0035 (Two-sided, derived from marginal odds ratio.) · Difference in proportions: 0.25 · 95% CI 0.078 to 0.395
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.1183 (Two-sided, derived from marginal (unadjusted) odds ratio.) · Odds ratio (or): 1.84 · 95% CI 0.905 to 3.809
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.1183 (Two-sided, derived from marginal odds ratio.) · Difference in proportions: 0.14 · 95% CI -0.035 to 0.290
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.0532 (Two-sided, derived from marginal (unadjusted) odds ratio.) · Odds ratio (or): 2.15 · 95% CI 1.035 to 4.585
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.0532 (Two-sided, derived from marginal odds ratio.) · Difference in proportions: 0.17 · 95% CI -0.004 to 0.311
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.0019 (Two-sided, derived from marginal (unadjusted) odds ratio.) · Odds ratio (or): 3.23 · 95% CI 1.539 to 6.989
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.0019 (Two-sided, derived from marginal odds ratio.) · Difference in proportions: 0.26 · 95% CI 0.089 to 0.400
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.0246 (Two-sided, derived from marginal (unadjusted) odds ratio.) · Odds ratio (or): 2.32 · 95% CI 1.119 to 4.944
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.0246 (Two-sided, derived from marginal odds ratio.) · Difference in proportions: 0.18 · 95% CI 0.014 to 0.330
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.0362 (Two-sided, derived from marginal (unadjusted) odds ratio.) · Odds ratio (or): 2.23 · 95% CI 1.076 to 4.762
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.0362 (Two-sided, derived from marginal odds ratio.) · Difference in proportions: 0.18 · 95% CI 0.005 to 0.321
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.1215 (Two-sided, derived from marginal (unadjusted) odds ratio.) · Odds ratio (or): 1.77 · 95% CI 0.871 to 3.668
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.1215 (Two-sided, derived from marginal odds ratio.) · Difference in proportions: 0.13 · 95% CI -0.044 to 0.281
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.1123 (Two-sided, derived from marginal (unadjusted) odds ratio.) · Odds ratio (or): 1.84 · 95% CI 0.882 to 3.935
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.1123 (Two-sided, derived from marginal odds ratio.) · Difference in proportions: 0.13 · 95% CI -0.040 to 0.274
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.0516 (Two-sided, derived from marginal (unadjusted) odds ratio.) · Odds ratio (or): 2.12 · 95% CI 1.006 to 4.626
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.0516 (Two-sided, derived from marginal odds ratio.) · Difference in proportions: 0.16 · 95% CI -0.011 to 0.298
SecondaryChanges From Baseline in Quantitative Cotinine Levels From Week 2 to Week 12

Changes in nicotine vaping measured by weekly quantitative cotinine levels from Week 2 to Week 12.

Time frame:
Baseline, Weeks 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Reported as:
Least squares mean · ng/mL
Changes From Baseline in Quantitative Cotinine Levels From Week 2 to Week 12
ng/mLPlacebo + Behavioral SupportCytisinicline + Behavioral Support
Change at Week 2-148.800 ± 26.8978-181.306 ± 18.5332
Change at Week 3-132.497 ± 26.8617-205.329 ± 18.5404
Change at Week 4-128.581 ± 27.0594-202.672 ± 18.5403
Change at Week 5-118.161 ± 26.9808-201.526 ± 18.6277
Change at Week 6-117.008 ± 27.0665-196.960 ± 18.7278
Change at Week 7-130.288 ± 27.5571-179.597 ± 18.6438
Change at Week 8-113.940 ± 27.3551-192.048 ± 18.8551
Change at Week 9-109.008 ± 27.6687-195.014 ± 18.8908
Change at Week 10-133.935 ± 27.2633-196.615 ± 18.8600
Change at Week 11-123.616 ± 27.3577-186.878 ± 18.8610
Change at Week 12-110.402 ± 27.3577-167.731 ± 18.8932
Statistical analysis
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Compound symmetry covariance matrix · p = 1.0000 (A compound symmetry covariance matrix was used. Bonferroni adjusted p-values are reported.) · Least squares (ls) means difference: -32.506 · 95% CI -155.1192 to 90.1072
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Compound symmetry covariance matrix · p = 1.0000 (A compound symmetry covariance matrix was used. Bonferroni adjusted p-values are reported.) · Ls means difference: -72.832 · 95% CI -195.3491 to 49.6842
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Compound symmetry covariance matrix · p = 1.0000 (A compound symmetry covariance matrix was used. Bonferroni adjusted p-values are reported.) · Ls means difference: -74.090 · 95% CI -197.2184 to 49.0381
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Compound symmetry covariance matrix · p = 1.0000 (A compound symmetry covariance matrix was used. Bonferroni adjusted p-values are reported.) · Ls means difference: -83.364 · 95% CI -206.4354 to 39.7066
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Compound symmetry covariance matrix · p = 1.0000 (A compound symmetry covariance matrix was used. Bonferroni adjusted p-values are reported.) · Ls means difference: -79.952 · 95% CI -203.5009 to 43.5976
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Compound symmetry covariance matrix · p = 1.0000 (A compound symmetry covariance matrix was used. Bonferroni adjusted p-values are reported.) · Ls means difference: -49.309 · 95% CI -174.2006 to 75.5817
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Compound symmetry covariance matrix · p = 1.0000 (A compound symmetry covariance matrix was used. Bonferroni adjusted p-values are reported.) · Ls means difference: -78.107 · 95% CI -202.8196 to 46.6046
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Compound symmetry covariance matrix · p = 1.0000 (A compound symmetry covariance matrix was used. Bonferroni adjusted p-values are reported.) · Ls means difference: -86.006 · 95% CI -211.7643 to 39.7529
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Compound symmetry covariance matrix · p = 1.0000 (A compound symmetry covariance matrix was used. Bonferroni adjusted p-values are reported.) · Ls means difference: -62.680 · 95% CI -187.1187 to 61.7592
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Compound symmetry covariance matrix · p = 1.0000 (A compound symmetry covariance matrix was used. Bonferroni adjusted p-values are reported.) · Ls means difference: -63.262 · 95% CI -187.9952 to 61.4704
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Compound symmetry covariance matrix · p = 1.0000 (A compound symmetry covariance matrix was used. Bonferroni adjusted p-values are reported.) · Ls means difference: -57.329 · 95% CI -182.1302 to 67.4727
SecondaryPercentage of Participants With Vaping Abstinence From Week 9 to 16

Vaping abstinence used quantitative saliva cotinine levels at \< 10 ng/mL for biochemical verification and participants' self-report of no vaping. Measurements were Weekly from Week 9 to 12 and one month for Week 16.

Time frame:
Weeks 9 to 16
Reported as:
Number · percentage of participants
Percentage of Participants With Vaping Abstinence From Week 9 to 16
percentage of participantsPlacebo + Behavioral SupportCytisinicline + Behavioral Support
Percentage of Participants With Vaping Abstinence From Week 9 to 1613.223.4
Statistical analysis
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.1470 (Two-sided, derived from marginal odds ratio.) · Odds ratio (or): 2.00 · 95% CI 0.820 to 5.319
  • Placebo + Behavioral Support vs Cytisinicline + Behavioral Support · Exact computations · p = 0.1470 (Two-sided, derived from marginal odds ratio.) · Difference in proportions: 0.10 · 95% CI -0.044 to 0.211

Adverse events

Collected over up to Week 16 ±3 days. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo + Behavioral Support0/53 (0%)0/53 (0%)26/53 (49.1%)
Cytisinicline + Behavioral Support0/106 (0%)0/106 (0%)42/106 (39.6%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPlacebo + Behavioral SupportCytisinicline + Behavioral Support
COVID-19Infections and infestations7/534/106
Abnormal dreamsPsychiatric disorders1/5313/106
NauseaGastrointestinal disorders6/535/106
InsomniaPsychiatric disorders1/5311/106
HeadacheNervous system disorders5/537/106
AnxietyPsychiatric disorders4/5310/106
FatigueGeneral disorders2/536/106
Upper respiratory tract infectionInfections and infestations3/536/106
Dry mouthGastrointestinal disorders2/532/106
Urinary tract infectionInfections and infestations2/531/106

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo + Behavioral SupportCytisinicline + Behavioral SupportTotal
Mean33.5 ± 10.9433.6 ± 11.1533.6 ± 11.05
Sex: Female, Male
Sex: Female, Male(Participants)Placebo + Behavioral SupportCytisinicline + Behavioral SupportTotal
Female295483
Male245377
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo + Behavioral SupportCytisinicline + Behavioral SupportTotal
Hispanic or Latino549
Not Hispanic or Latino48103151
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo + Behavioral SupportCytisinicline + Behavioral SupportTotal
Asian336
Black or African American5914
White4392135
Other, Not Specified235
08

Study locations

5 sites
  • Alliance for Multispecialty Research, LLC
    Lexington, Kentucky 40509, United States
  • Massachusetts General Hospital - Clinical Genetic Research Facility
    Boston, Massachusetts 02114, United States
  • Rochester Clinical Research, Inc
    Rochester, New York 14609, United States
  • Coastal Carolina Research Center
    North Charleston, South Carolina 29405, United States
  • Alliance for Multispecialty Research, LLC
    Knoxville, Tennessee 37920, United States
09

References and documents

Publications

  • Rigotti NA, Benowitz NL, Prochaska JJ, Cain DF, Ball J, Clarke A, Blumenstein BA, Jacobs C. Cytisinicline for Vaping Cessation in Adults Using Nicotine E-Cigarettes: The ORCA-V1 Randomized Clinical Trial. JAMA Intern Med. 2024 Aug 1;184(8):922-930. doi: 10.1001/jamainternmed.2024.1313. PubMed 38709500 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Feb 2023, 7 months.

Results were first posted in Jan 2026, 2 years 10 months after primary completion. A results delay was requested in Feb 2024.

Of 16 phase 2 interventional studies under Vaping, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 37. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2022
First posted
Jun 24, 2022
StartActual
Jul 13, 2022
Primary completionActual
Feb 28, 2023
CompletionActual
Feb 28, 2023
Results delay requested
Feb 26, 2024
Results first posted
Jan 14, 2026
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05431387
Responsible party
Sponsor
First posted
Jun 24, 2022
Start date
Jul 13, 2022
Primary completion
Feb 28, 2023
Completion
Feb 28, 2023
Results posted
Jan 14, 2026
Last update
Jan 14, 2026

Study contacts

Daniel Cain, Vice-President Clinical Research
study director · Achieve Life Sciences, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cytisine

Start the discussion